Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Medication


Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus

October 21st 2020

Periodical dosing of vitamin B12 should be performed in the case of patients with Type 2 Diabetes Mellitus treated with metformin, especially if they associate anemia and/or peripheral diabetic polyneuropathy (Diabetes, Metabolic Syndrome and Obesity)

Categories: Medication, News
Tags: anaemia, metformin, Type 2 Diabetes

Categories: Medication
Tags: anaemia, metformin, Type 2 Diabetes

SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes

October 12th 2020

Treatment with SGLT2 inhibitors results in clear and consistent reductions in cardiovascular, kidney and mortality outcomes regardless of whether patients are receiving or not receiving metformin (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: SGLT2 inhibitors

Categories: Medication
Tags: SGLT2 inhibitors

Metformin use in prediabetes: is earlier intervention better?

October 11th 2020

The largest reductions in both incidence of diabetes and FPG occurred in prediabetic persons with a higher level of FPG at baseline. Metformin was able to stabilise insulin sensitivity and was more effective in persons with more pronounced IFG (Acta Diabetologica)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin

Effects of SGL2 inhibitors on liver parameters and steatosis: a meta‐analysis of randomized clinical trials

October 4th 2020

Treatment with SGLT2 inhibitors improves liver structure and function in patients with type 2 diabetes. This meta‐analysis suggests that SGLT2 inhibitors are a promising pharmacological approach to NAFLD (Diabetes/Metabolism Research and Reviews)

Categories: Medication, News
Tags: NAFLD, SGLT2 inhibitors

Categories: Medication
Tags: NAFLD, SGLT2 inhibitors

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19

September 30th 2020

In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment (Diabetes Care)

Categories: Medication, News
Tags: COVID-19, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: COVID-19, sitagliptin, Type 2 Diabetes

Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial

September 27th 2020

Eighteen months of metformin treatment in combination with insulin compared with insulin alone increased early drop in OBP indicating an adverse effect of metformin on CAN independent of vitamin B12, MMA HbA1c (Cardiovascular Diabetology)

Categories: Medication, News
Tags: hypotension, insulin, metformin, Type 2 Diabetes

Categories: Medication
Tags: hypotension, insulin, metformin, Type 2 Diabetes

Dapagliflozin in Patients with Chronic Kidney Disease

September 24th 2020

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo (NEJM)

Categories: Medication, News
Tags: CKD, dapagliflozin

Categories: Medication
Tags: CKD, dapagliflozin

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

September 22nd 2020

Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes (NEJM)

Categories: Medication, News
Tags: insulin, Type 2 Diabetes

Categories: Medication
Tags: insulin, Type 2 Diabetes

Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes

September 15th 2020

This review summarizes pharmacogenomic evidence of some current antidiabetic agents applied in clinical settings, and highlights potential drugs with new targets for diabetes, which represent a more effective treatment in the future (Diabetes Therapy)

Categories: Medication, News

Categories: Medication

Potential Unrealized Mortality Benefit of GLP‐1 Receptor Agonists and SGLT2 Inhibitors

September 10th 2020

This analysis indicates unrealized opportunities to reduce mortality in selected Veterans with T2D and CAD via increased use of GLP‐1RA and SGLT2i (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP‐1RA, mortality, SGLT2 inhibitors

Categories: Medication
Tags: GLP‐1RA, mortality, SGLT2 inhibitors

Lower Cardiorenal Risk with Sodium‐Glucose Cotransporter‐2 Inhibitors versus Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases

September 8th 2020

In this multinational observational study, SGLT2i was associated with lower risk of heart failure and chronic kidney disease versus DPP4i in T2D patients otherwise free from both cardiovascular and renal disease (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: Cardiorenal, DPP-4 inhibitors, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: Cardiorenal, DPP-4 inhibitors, SGLT2 inhibitors, Type 2 Diabetes

Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes

September 7th 2020

Overall, the improved postprandial blood glucose levels and increase in incretins observed in the absence of changes in insulin sensitivity and gluconeogenesis, support an enteroinsular mechanistic pathway in youth with type 2 diabetes treated with short-term metformin (Diabetologia)

Categories: Medication, News
Tags: incretin, metformin, Type 2 Diabetes

Categories: Medication
Tags: incretin, metformin, Type 2 Diabetes

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

September 3rd 2020

Based on the current understandings and lessons learned from the most recent studies, we discussed the importance of future research on the safety and efficacy of SGLT2 inhibitor in clinical situations of HF other than those examined in previous cardiovascular outcome trials (Cardiovascular Diabetology)

Categories: Medication, News
Tags: SGLT2 inhibitors

Categories: Medication
Tags: SGLT2 inhibitors

Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis

September 2nd 2020

These data indicate that SGLT-2is is more beneficial to MACE and all-cause mortality in T2DM patients than DPP-4is (Primary Care Diabetes)

Categories: Medication, News
Tags: DPP4i, GLP1 receptor agonist, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: DPP4i, GLP1 receptor agonist, SGLT2 inhibitors, Type 2 Diabetes

Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis

September 2nd 2020

The clinical effectiveness of liraglutide is maintained long term (up to 5 years). Liraglutide treatment is not associated with higher total direct healthcare costs (Diabetes Therapy)

Categories: Medication, News
Tags: liraglutide, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, Type 2 Diabetes

Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis

September 2nd 2020

The addition of DPP4i to insulin is associated with a statistically significant reduction in glycemic control as measured by HbA1c, fasting plasma glucose, and 2-h postprandial glucose, without increasing the risk of hypoglycemia and weight gain. These conclusions were also observed in both stable-dose and flexible-dose insulin subgroups (Diabetes Therapy)

Categories: Medication, News
Tags: DPP4i, insulin, Type 2 Diabetes

Categories: Medication
Tags: DPP4i, insulin, Type 2 Diabetes

Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis

August 26th 2020

This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy (Journal of Clinical Endocrinology & Metabolism)

Categories: Medication, News
Tags: Empagliflozin, metformin, semaglutide, Type 2 Diabetes

Categories: Medication
Tags: Empagliflozin, metformin, semaglutide, Type 2 Diabetes

Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?

August 20th 2020

In clinical trials, oral semaglutide 14 mg reduced mean HbA1c by approximately 1.1–1.5% and reduced body weight by up to 5 kg. The most common side effects were gastrointestinal, mainly mild-to-moderate and transient nausea. Oral semaglutide may offer a practical and effective means of managing people living with T2D who require treatment intensification, and may change the paradigm of care in the primary care setting (Primary Care Diabetes)

Categories: Medication, News
Tags: semaglutide, Type 2 Diabetes

Categories: Medication
Tags: semaglutide, Type 2 Diabetes

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study

August 18th 2020

Metformin use is associated with early risk of anemia in individuals with type 2 diabetes, a finding consistent across two RCTs and replicated in one real-world study (Diabetes Care)

Categories: Medication, News
Tags: anaemia, metformin, Type 2 Diabetes

Categories: Medication
Tags: anaemia, metformin, Type 2 Diabetes

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

August 18th 2020

This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability (Diabetes Therapy)

Categories: Medication, News
Tags: Glucagon-Like Peptide 1 Receptor Agonist, semaglutide, Type 2 Diabetes

Categories: Medication
Tags: Glucagon-Like Peptide 1 Receptor Agonist, semaglutide, Type 2 Diabetes
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 42
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesNovo NordiskAstraZenecaSanofi Diabetes

Silver Sponsors

Abbott Diabetes CareAmgenWelsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership